News -Imalia Announces Completion of Clinical Phase of Indian Randomized Pilot Study on IMA001 in Sickle Cell Disease

Imalia Announces Completion of Clinical Phase of Indian Randomized Pilot Study on IMA001 in Sickle Cell Disease

Completion of the clinical phase of randomized, double blind, placebo controlled pilot study conducted in India to evaluate safety and efficacy of orally administered IMA001 in sickle cell disease patients.

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe to our newsletter
Related Posts
Previous
Next